P18 Adjusted Comparison of Teclistamab Versus Real-World Physician ’s Choice (RWPC) of Therapy in Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Patients with RRMM who receive ≥3 prior lines of therapy (LOT) have limited treatment options. Teclistamab is the only approved BCMA×CD3 bispecific antibody with a personalized, weight-based dosing schedule for the treatment of TCE RRMM. We assessed the comparative effectiveness of teclistamab vs RWPC of therapy.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M.V. Mateos, A. Chari, S.Z. Usmani, H. Goldschmidt, K. Weisel, K. Qi, A. Londhe, S. Nair, X. Lin, L. Pei, E. Ammann, K. Chastain, T. Parekh, A. Marshall, M. Slavcev, P. Moreau Source Type: research